Loading...
DTIL logo

Precision BioSciences, Inc.NasdaqCM:DTIL Stock Report

Market Cap US$203.3m
Share Price
n/a
1Y88.5%
7D21.2%
1D3.8%
Portfolio Value
​
View

Precision BioSciences, Inc.

NasdaqCM:DTIL Stock Report

Market Cap: US$203.3m

Precision BioSciences (DTIL) Stock Overview

A clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. More details

DTIL fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 90.3% below our estimate of its fair value

Revenue is forecast to grow 27.58% per year

Trading at good value compared to peers and industry

Risk Analysis

Earnings are forecast to decline by an average of 3% per year for the next 3 years

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years


DTIL Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW491,196 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
491,196 investors already sharing narratives
View all narratives

Precision BioSciences, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Precision BioSciences
Historical stock prices
Current Share PriceUS$8.18
52 Week HighUS$8.82
52 Week LowUS$3.53
Beta1.28
1 Month Change29.43%
3 Month Change40.55%
1 Year Change88.48%
3 Year Change-49.33%
5 Year Change-97.61%
Change since IPO-98.44%

Recent News & Updates

Analysis Article • May 13

Analyst Forecasts For Precision BioSciences, Inc. (NASDAQ:DTIL) Are Surging Higher

Precision BioSciences, Inc. ( NASDAQ:DTIL ) shareholders will have a reason to smile today, with the analysts making...

Recent updates

Analysis Article • May 13

Analyst Forecasts For Precision BioSciences, Inc. (NASDAQ:DTIL) Are Surging Higher

Precision BioSciences, Inc. ( NASDAQ:DTIL ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Dec 29

Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026

Summary Precision BioSciences offers high-risk, high-reward potential, trading below cash with key HBV and DMD data catalysts expected in 2026. PBGENE-HBV targets both cccDNA and integrated HBV DNA, aiming for a functional HBV cure superior to downstream competitors. Recent $75M capital raise extends DTIL's cash runway through major readouts, supporting continued clinical development and operational flexibility. Risks include potential safety events, competitive efficacy, and uncertain milestone/royalty revenue from partnered programs. Read the full article on Seeking Alpha
Analysis Article • Aug 06

Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts

Celebrations may be in order for Precision BioSciences, Inc. ( NASDAQ:DTIL ) shareholders, with the analysts delivering...
Analysis Article • Jun 23

It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks

Precision BioSciences, Inc. ( NASDAQ:DTIL ) shares have had a horrible month, losing 29% after a relatively good period...
Analysis Article • Mar 14

Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Dec 08

Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Sep 02

Precision BioSciences appoints chief business officer from within ranks, rejigs co-founders' roles

Precision BioSciences promoted Cindy Atwell to chief business officer and carried out other leadership changes. Atwell, who was serving as senior vice president of Business Development and Alliance Management, will continue to oversee the Business Development and Alliance functions with added responsibility for Project and Portfolio Management, the company said in a Sept. 2 press release. Jeff Smith, co-founder and formerly chief technology officer, was promoted to chief research officer and will assume responsibility for the management and direction of the company’s research programs and report directly to the CEO Michael Amoroso. Precision added that Derek Jantz, co-founder and chief scientific officer, will step down from the board to focus his time partnering with Amoroso in making company strategy and managing relationships with external stakeholders. Jantz departure would reduces the number of management members serving on the board, the company added. DTIL +1.27% to $1.60 premarket Sept. 1

Shareholder Returns

DTILUS BiotechsUS Market
7D21.2%5.4%1.4%
1Y88.5%41.5%19.1%

Return vs Industry: DTIL exceeded the US Biotechs industry which returned 37.9% over the past year.

Return vs Market: DTIL exceeded the US Market which returned 21.1% over the past year.

Price Volatility

Is DTIL's price volatile compared to industry and market?
DTIL volatility
DTIL Average Weekly Movement9.8%
Biotechs Industry Average Movement10.3%
Market Average Movement7.3%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: DTIL has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: DTIL's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200666Michael Amorosoprecisionbiosciences.com

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy.

Precision BioSciences, Inc. Fundamentals Summary

How do Precision BioSciences's earnings and revenue compare to its market cap?
DTIL fundamental statistics
Market capUS$203.32m
Earnings (TTM)-US$44.48m
Revenue (TTM)US$45.07m
4.7x
P/S Ratio
-4.7x
P/E Ratio

Is DTIL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DTIL income statement (TTM)
RevenueUS$45.07m
Cost of RevenueUS$0
Gross ProfitUS$45.07m
Other ExpensesUS$89.56m
Earnings-US$44.48m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-1.72
Gross Margin100.00%
Net Profit Margin-98.70%
Debt/Equity Ratio29.5%

How did DTIL perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/02 05:02
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Precision BioSciences, Inc. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Debjit ChattopadhyayGuggenheim Securities, LLC
Debjit ChattopadhyayH.C. Wainwright & Co.
Patrick TrucchioH.C. Wainwright & Co.